Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Mechanism and amelioration of recombinant human interleukin-11 (rhIL-11)-induced anemia in healthy subjects
Autore:
Dykstra, KH; Rogge, H; Stone, A; Loewy, J; Keith, JC; Schwertschlag, US;
Indirizzi:
Genet Inst, Cambridge, MA 02140 USA Genet Inst Cambridge MA USA 02140Genet Inst, Cambridge, MA 02140 USA
Titolo Testata:
JOURNAL OF CLINICAL PHARMACOLOGY
fascicolo: 8, volume: 40, anno: 2000,
pagine: 880 - 888
SICI:
0091-2700(200008)40:8<880:MAAORH>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
PITUITARY-ADRENAL AXIS; GROWTH-FACTOR; CELLS; SECRETION; DISEASE; VOLUME;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: Schwertschlag, US Genet Inst, 87 Cambridge Pk Dr, Cambridge, MA 02140 USA Genet Inst 87 Cambridge Pk Dr Cambridge MA USA 02140 USA
Citazione:
K.H. Dykstra et al., "Mechanism and amelioration of recombinant human interleukin-11 (rhIL-11)-induced anemia in healthy subjects", J CLIN PHAR, 40(8), 2000, pp. 880-888

Abstract

Recombinant human interleukin-11 (rhIL-11), or Neumega(R) rhIL-11 Growth Factor, is a recombinant cytokine that stimulates megakalyocytopoiesis, increases platelet production, and also has shown anti-inflammatory and immune-modulating activity Mild, reversible anemia was the most common adverse event observed in clinical studies and was demonstrated to be related to hemodilution. The purpose of this study was to examine the renal mechanisms of the rhIL-11-induced volume retention and devise a possible therapeutic intervention to ameliorate this effect. Eighteen healthy volunteers (9 male and 9 female) on a controlled sodium (180 mEq/day) and potassium (120 mEq/day) diet were randomized to one of six treatment sequences in a three-period crossover design. Each subject received 25 mu g/kg IL-11 SC once daily, 25 mug/kg IL-ll SC once daily + Maxzide-25(R) twice daily or placebo for 7 daysin a crossover design. There was a 14-day washout period between treatmentperiods. Renal clearance parameters indicated that mean sodium excretion was decreased compared to placebo within 8 hours after dosing with rhIL-11, with these results reaching statistical significance 8 to 16 hours postdose(p < 0.01). The cumulative sodium excretion (mEq +/- SD) over the 7-day treatment period for each respective treatment group was the following: rhIL-11 = 833 +/- 154, rhIL-11 + Maxzide-25(R) twice daily = 1114 +/- 178, and placebo = 982 +/- 193 (p < 0.01). Hemoglobin concentration and hematocrit values, used as indicators of hemodilution, decreased in the rhIL-11-treated group as compared to the baseline and placebo groups (p < 0.01). Concurrentdosing with Maxzide-25(R) twice daily reduced the rhIL-11-associated hemodilution by about 50%. (C) 2000 the American College of Clinical Pharmacology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/21 alle ore 02:57:34